+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative evaluation of the Roche HIV Monitor Assay and the Organon Teknika Nuclisens NASBA Assay for determining HIV viral load



Comparative evaluation of the Roche HIV Monitor Assay and the Organon Teknika Nuclisens NASBA Assay for determining HIV viral load



Abstracts of the General Meeting of the American Society for Microbiology 101: 263



The goal of this research was to compare the Roche HIV Monitor Assay with the Organon Teknika Nuclisens NASBA Assay for quantitative HIV viral load determination. A total of 72 separate samples were analyzed. All samples were processed with the Organon Teknika Extractor system for automated extraction and isolation of nucleic acids. Quantitation standards supplied by the vendors were mixed with the samples prior to processing to control for extraction efficiency. Due to the different quantitation standards employed by the two tests, samples had to be separately processed through the extractor for the different methods. The isolated nucleic samples were subsequently processed for viral load determination according to the vendor's kit instructions. The final calculations for viral copies per ml were performed according to the manufacturer supplied protocol for the Roche assay. Viral load calculations using the Organon Teknika assay were provided with the print out from the Nuclisens ECL reader using the HIV QT protocol. The majority of the samples (69/72, 96%) demonstrated good correlation of the two methods (all less than 0.5 log difference, and the majority less than 0.25 log difference). Two samples had an approximate 0.5 log variance and in one sample there was a variance of slightly under 1 log (550,000 for Roche assay and 58,000 for the Organon method). These results indicate that the two methods provide essentially the same quantitative value for HIV viral load. This suggests that there may be limited need to "re-baseline" test patients when switching between these two methods.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034612659

Download citation: RISBibTeXText


Related references

Comparison of Roche MONITOR and Organon Teknika NucliSens assays to quantify human immunodeficiency virus type 1 RNA in cerebrospinal fluid. Journal of Clinical Microbiology 39(4): 1612-1614, 2001

Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. Journal of Clinical Microbiology 38(11): 4034-4041, 2000

Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. Journal of Clinical Virology 49(3): 198-204, 2010

Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals. Antiviral Therapy 14(8): 1189-1193, 2009

Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clinical Infectious Diseases 48(2): 260-262, 2009

The role of HIV-1 viral load testing using the Roche Amplicor monitor assay in the diagnosis of recent HIV infection. AIDS 12(Suppl. 4): S74, 1998

Evaluation of the NucliSens EasyQ v2.0 assay in comparison with the Roche Amplicor v1.5 and the Roche CAP/CTM HIV-1 Test v2.0 in quantification of C-clade HIV-1 in plasma. Plos one 9(8): E103983, 2014

Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. Journal of Virological Methods 163(2): 253-257, 2010

Comparative analysis of quantification of viral load in patients infected with hepatitis C virus: quantiplex HCV RNA assay and amplicor monitor assay. Revista Espanola de Enfermedades Digestivas 91(8): 569-582, 1999

Comparative evaluation of the Abbott HIV-1 RealTime™ assay with the Standard Roche COBAS® Amplicor™ HIV-1 Monitor® Test, v1.5 for determining HIV-1 RNA levels in plasma specimens from Pune, India. Journal of Virological Methods 191(1): 82-87, 2013

Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. Journal of Clinical Microbiology 47(7): 2209-2217, 2009

Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Load. Journal of Clinical Microbiology 53(11): 3458-3465, 2015

Evaluation of a new NASBA assay for the qualitative detection of hepatitis C virus based on the NucliSens Basic Kit reagents. Journal of Clinical Virology 29(2): 84-91, 2004

Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR Version 1.5 conventional PCR assay. Journal of Clinical Microbiology 45(11): 3616-3619, 2007

Clinical evaluation of HIV-1 viral load measurements and the detection of cytomegalovirus by PCR and the NucliSens CMV pp67 assay in cerebrospinal fluid from AIDS patients with specific CNS disease. Abstracts of the General Meeting of the American Society for Microbiology 99: 172, 1999